TrialBritish journal of clinical pharmacology2019

Erlotinib treatment induces cytochrome P450 3A activity in non-small cell lung cancer patients.

Anna Svedberg et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.